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Abstract
Kaposi’s sarcoma-associated herpesvirus (KSHV) is considered to be a necessary, but not sufficient, causal agent of Kaposi’s
sarcoma (KS). All forms of KS are characterized by the proliferation of spindle-shaped cells, and most (.90%) spindle cells
from KS lesions are latently infected with KSHV. During KSHV latency, only a few viral genes are expressed. Among those
latent genes, the ORF 73 gene encodes the latency-associated nuclear antigen (LANA), which is critical for the establishment
and maintenance of the latent KSHV infection. Much evidence suggests that many cytokines can increase the frequency and
aggressiveness of KS. In this study, a microarray analysis of KS and normal tissues revealed that multiple cytokines and
cytokine receptors are regulated by KSHV latent infection. Of special interest, IL-22R1 transcript level was found to be down-
regulated in the KS tissue. To study the possible regulation of IL-22R1 by LANA, the IL-22R1 promoter was constructed and
found to contain a LANA-binding site (LBS). LANA was demonstrated to down-regulate IL-22R1 expression via direct binding
to the LBS located within the IL-22R1 promoter region. Furthermore, KSHV latently infected cells showed an impaired
response to IL-22 stimulation. These results suggest that LANA can regulate host factor expression by directly binding to a
cis-acting element within the factor’s promoter to benefit latent viral infection and suppression of the antiviral immune
response.
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Introduction
Kaposi’s sarcoma (KS) is a multicentric angioproliferative
disorder that frequently involves the skin [1]. Kaposi’s sarcoma-
associated herpesvirus (KSHV) is considered to be a necessary, but
not sufficient, causal agent of KS. KSHV is also associated with
primary effusion lymphoma (PEL) and a subset of multicentric
Castleman’s disease [2]. KS can be subdivided into three clinical
subtypes: cutaneous, mucocutaneous, and visceral types. All forms
of KS are characterized by the proliferation of spindle-shaped
cells, angiogenesis, inflammatory cell infiltration, and edema [3].
In early-stage KS, large numbers of inflammatory cells, including
lymphocytes and macrophages, are recruited into KS lesions [4].
These cells produce high levels of proinflammatory cytokines and
growth factors. Cytokines produced by inflammatory cells induce
normal endothelial cells to acquire the features of KS spindle cells
and to induce production of angiogenic factors [5]. Several
cytokines and growth factors have been shown to support the
growth of cultured KS spindle cells; these include IL-1b, IL-6, the
soluble IL-6 receptor a, oncostatin M, and TNF-a [6,7]. The
evidence suggests that cytokines can increase the frequency and
aggressiveness of KS by enhancing the effect of angiogenic factors
or by reactivating KSHV reinfection, which is etiologically closely
associated with KS [8].
Most (.90%) spindle cells from KS lesions are latently infected
with KSHV, and only a few viral genes are expressed during
KSHV latency [9]. Among those latent genes, the ORF 73 gene,
which encodes the latency-associated nuclear antigen (LANA), is
critical for the establishment of a latent KSHV infection. LANA is
a large (1162 amino acid), multifunctional, constitutively expressed
protein that is required for viral episome maintenance in
proliferating cells [10]. Many researchers have found that LANA
can function as a transcriptional modulator of various cellular and
viral promoters, including its own promoter [11,12,13,14,15]. The
activation of transcription by LANA is directed by many
promoters containing binding sites for cellular proteins including
ATF, AP-1, CAAT, or Sp1, which are linked to a TATA box [16].
LANA also contributes to broad repressive effects on transcription
[17]. Although some of the transcriptional repression mediated by
LANA occurs indirectly via interactions with corepressors
including mSin3, SAP30, CIR, the methyl CpG-binding protein
MeCP2, or the histone methyltransferase SUV39H1 [18,19,20],
this viral protein inhibits TGF-b signaling through epigenetic
silencing of the TGF-b typeareceptor [21]. Direct binding of
LANA to DNA has also been reported to result in the
transcriptional repression of a viral gene [22].
IL-22R1 (interleukin 22 receptor 1a), whose alternative names
include IL-22R, cytokine receptor family 2 member 9 (CRF2-9), is
a 574 amino acid single-pass type I membrane protein belonging
to the type II cytokine receptor family. IL-22R1-expressing tissues
include barrier organs, lung, liver, kidney, colon and pancreas. IL-
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IL-22, IL-20, or IL-24 [23]. IL-22 is a member of the IL-10
cytokine family and is primarily produced by Th1, Th17, Th22
and NK cells [24,25]. IL-22 first binds to the IL-22R1
extracellular domain with high affinity, and then IL-10R2 can
sequentially recognize and bind to the IL-22/IL-22R1 binary
complex [26]. This ternary complex activates the JAK/STAT
signaling pathway, strongly activating STAT3 and weakly
activating STATs 1 and 5, which leads to the diverse biological
effects of IL-22. Furthermore, this complex could also activate the
extracellular signal-regulated kinase (ERK), c-Jun N-terminal
kinase (JNK), and p38 MAP kinase pathways in a rat hepatoma
cell line [27]. IL-22 can be either pathogenic and inflammatory or
protective depending upon affected tissue and the co-expression of
inflammatory (IL-8 and CRP) or regulatory (SOCS 3, IL-10, and
antibacterial peptides) molecules.
The present study demonstrates that several cytokines and
cytokine receptors are regulated by KSHV latent infection, and
that the transcription level of IL-22R1 was down-regulated in KS
tissue compared with normal tissue. KSHV-positive cells also
exhibited impaired responses to IL-22 stimulation. Furthermore,
KSHV LANA was shown to be responsible for the down-
regulation of IL-22R1 expression through direct binding to a cis-
acting element that located within the IL-22R1 promoter region.
Our results suggest that LANA may have evolved in multi-
pathways to modify the cellular environment to benefit viral
survival.
Results
Distinct expression levels of cytokines and cytokine
receptors in KS lesions versus normal tissue
KSHV induces transcriptional reprogramming of infected cells
[28] to adapt the environment for the benefit of the virus. To
further identify cellular genes regulated upon the formation of a
KS lesion, gene expression profiles were compared between
Kaposi sarcoma and normal skin tissues by cDNA-microarray. KS
tissue from a nodular lesion representing the most advanced stage
of KS disease and normal tissue taken near the KS lesion were
used. The analysis showed that a total of 2980 genes were
significantly (p,0.05) up- or down-regulated (.2-fold) in the KS
tissue compared to the normal tissue. In particular, a change in the
expression levels of a subset of cytokines and cytokine receptors in
the KS lesion was identified (Figure 1). IL-6, IL-1b, and IL-10
expression levels were all elevated more than two-fold; these
cytokines have all been previously reported to be important
contributors to the growth, survival, and spread of KSHV-
associated disease [29,30]. Notably, the gene expression level of
IL-18, an IFN-c inducing factor [31], was decreased 62%. We
hypothesize that IL-18 may also be a key factor in KS
pathogenesis.
Expression levels of several interleukin receptors, including IL-
1R2, IL-22R1, IL-23R1, IL-28R1, IL-20R2, and IL-22R2, were
dramatically down-regulated in KS tissue (Figure 1). Among these
receptors, IL-22R1 and IL-20R2 can form a dimer to be
recognized by IL-20 and IL-24 [23]. Recently, increasing data
has shown that IL-20 and IL-24 play important roles in host
inflammatory regulation [32], anti-angiogenesis [33,34] and cell
growth inhibition [35]. IL-22R1 was reported to drive inflamma-
tion in a mouse model [36]. Interestingly, the reduced expression
of IL-22R1 in KSHV-infected cells was also reported by Wang et
al. [28]. IL-22R2, a soluble, naturally occurring IL-22 antagonist,
shares its amino acid sequence homology with IL-22R1 and is
encoded by a gene physically adjacent to IL-20R1 [37]. IL-22R2
exhibited a similar reduced expression pattern, raising the
possibility that the biological functions of IL-22 may be impaired
in KS tissue. The down-regulation of IL-22R1 could be relevant to
KSHV latency and pathogenesis.
LANA down-regulates IL-22R1 promoter activity in a
dose-dependent manner
To investigate the regulation of IL-22R1 gene expression, a
reporter plasmid (pIL22R1) was constructed by cloning the
putative wide-type IL-22R1 promoter including the 59 untrans-
lated region (22139 to +39, with +1 being the transcription
initiation site) and inserting it upstream of the luciferase gene in
the promoterless pGL3-basic vector. Transient transfection of
pIL22R1 into 293T cells resulted in a greater than 40-fold increase
in luciferase activity compared with the pGL3-basic vector control,
demonstrating that this DNA fragment contains significant
promoter activity (Figure 2A). Therefore, the IL-22R1 promoter
pIL22R1 was fully functional. To further characterize the IL-
22R1 promoter, a series of truncated mutants were constructed
and all showed activity in 293T cells (Figure 2A). When an
upstream promoter region (22139 to 21172) was deleted, the
promoter activity was found to elevate about 4-fold, indicating that
a negative regulation element may exist in the region (Figure 2A).
Similar results were also obtained in human umbilical vein
endothelial cells (HUVECs) (data not shown).
Viral gene expression has been demonstrated to be highly
restricted in KSHV latent infections, and most of the latency-
expressed genes are important for maintaining viral latency by
modulating various cellular pathways [2]. LANA has been
demonstrated to regulate transcription [11], so we hypothesized
that LANA could be responsible for the downregulation of IL-
22R1. To test more possibilities in transcription regulation, we
used a longer reporter, pIL22R1 (22139 to +39), to do the
following experiments. pIL22R1 (22139 to +39) was co-
transfected with different concentrations of full-length LANA
expression vector pcDNA-LANA into 293T cells and HUVEC
cells, and promoter activity was measured as relative luciferase
units (RLU). As shown in Fig. 2B, the IL-22R1 promoter activity
was repressed by LANA in a dose-dependent manner in both cells.
The expression of LANA was confirmed in 293T cells and
HUVECs by Western Blotting. Our results indicated that IL-22R1
can be transcriptionally down-regulated by the KSHV latent
protein LANA.
The LBS-like sequence is required for LANA to
down-regulate IL-22R1 expression
LANA has been shown to specifically bind to two sites termed
LANA binding site 1 (LBS1) and LANA binding site 2 (LBS2)
within the terminal repeats of the viral genome. The core binding
motif is GCCCCATGCCCGGGCG, and 13 of the 16 bp are
conserved between the two sites [38]. To determine whether any
LANA response elements were present in the IL-22R1 promoter
region, a sequence analysis of the promoter region of the IL-22R1
gene was performed. An element (264 to 248) with only one base
pair mismatch (250 T/C) to LBS1 was identified within the IL-
22R1 promoter region. Due to the similarity in the nucleotide
sequence, we hypothesized that LANA may have a potential
binding activity to this element and this LBS-like sequence may
play a role in the LANA-mediated repression of IL-22R1
expression. To confirm our hypothesis, we deleted nucleotides
264 to 251 from the pIL22R1 to construct pIL22R1DLBS-like
(264 to 251), and introduced substitution mutations in the LBS-
like sequence to construct pIL22R1-mLBS-like (Figure 3A).
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the IL-22R1 WT promoter in a dose-dependent manner, whereas
it had a much lower effect on the repression of pIL22R1DLBS-like
and minimal effect on the activity of pIL22R1-mLBS-like. The
binding domain of LANA to the LBS region has been reported to
localize to residues 996–1139 [39]. When the pGL3-IL22R1
promoter was co-transfected with pcDNA-LANA-C (C-terminus
of LANA, a.a. 951–1162), the wild type IL-22R1 promoter activity
was shown to be down-regulated in dose-dependent manner
(Figure 3C). However, LANA-C did not appear to down-regulate
pIL22R1DLBS-like or pIL22R1-mLBS-like promoter activity
(Figure 3C). These data strongly suggest that the down-regulation
of the IL-22R1 promoter by LANA requires an LBS-like sequence
and that LANA-C can bind to LBS and affect the regulation of
IL22R1 expression similarly to full-length LANA. LBS-like
sequence-dependent down-regulation of the IL-22R1 promoter
was also observed to the same extent in HUVEC cells (Figure 3D).
The expression of LANA and LANA-C were confirmed by
western blot.
LANA binds to the LBS-like sequence in the IL-22R1
promoter in vitro
To test whether LANA can bind to the LBS-like sequence
located in the IL-22R1 promoter, EMSA was performed. The His-
tagged C-terminus of LANA was purified from E.coli BL21 cells
that were transformed with pET-his-LANA-C. Three probes, LBS
with a core LBS1 sequence (37 bp), an LBS-like region (269 to
234) from pIL22R1 containing the LBS-like sequence, and a
DNA fragment with a scramble mutation in the LBS-like sequence
named mLBS-like, were designed and 59-labeled with biotin
(Figure 4A). Our results demonstrate that LANA-C bound to the
IL-22R1 LBS-like sequence with an affinity similar to that of
LBS1, which has been previously demonstrated to bind with
LANA with high affinity [38] (Figure 4B, lanes 2 and 6). However,
the LANA-C protein did not bind the negative control, a DNA
fragment from M13 DNA or the probe bearing mutants in the
LBS-like sequence (Figure 4B, lanes 4 and 8). Competition with
the 10-fold excess unlabeled wild type probe (LBS-like fragment),
but not with the mutated LBS-like sequence (mLBS-like),
abolished the shifted band (protein-DNA complex) (Figure 4C,
lanes 3 and 4), demonstrating that this complex represents a
specific interaction between LANA and the LBS-like sequence.
LANA binds to the LBS-like sequence in IL-22R1 promoter
in vivo
To further verify whether LANA can bind to the LBS-like
sequence in the IL-22R1 promoter in vivo, ChIP assays were
performed using an anti-FLAG antibody on samples from cross-
linked 293T cells transfected with a full length LANA expression
plasmid pFLAG-LANA or one of the two truncated forms of
LANA, pFLAG-LANA1–939 and pFLAG-LANA933–1162.T o
amplify the ChIP signal, pIL22R1 was co-transfected in each
experimental group. The cross-link reversed DNAs were PCR-
amplified using the two primer pairs shown in Figure 5A. Primer
pair 1 was designed to amplify a 197 bp sequence containing the
LBS-like sequence. Primer pair 2 was designed to amplify a
238 bp sequence that was located approximately 2 kb away from
the IL-22R1 promoter LBS-like sequence and was used as a
negative control. As shown in Figure 5B, a band of 197 bp was
PCR-amplified using primer pair 1 from the immunoprecipitated
chromatin of the FLAG-LANA or the FLAG-LANA933–1162
expressing cell lysate, but not from the immunoprecipitated
chromatin of the FLAG or FLAG-LANA1–939 expressing cell
lysate. The 238-bp fragment could not be visualized in all groups.
These data demonstrate that both the full-length and the C-
terminus of LANA can bind specifically to the LBS-like sequence
that is located within the IL-22R1 promoter region in vivo. Taken
together, our results support the idea that the LANA protein is
capable of binding to a cis-element located within the IL-22R1
promoter region.
KSHV-infected cells show impaired response to IL-22
stimulation
Unlike other members of the IL-10 family, IL-22 can activate
the JAK/STAT pathway, phosphorylating STATs 1, 3 and 5, and
the three major MAPK pathways, inducing the phosphorylation of
ERK1/2, JNK, and p38 kinase after interaction with the IL-
22R1/IL-10R2 receptor complex [40]. To further investigate
Figure 1. Expression levels of cytokines and cytokine receptors in KS lesions vs. normal tissues. A cDNA microarray analysis was
performed to compare the gene expression between KS tissue and normal tissue. Differentially expressed interleukin-associated genes are listed
(Ratio $2o r#0.5 and p value of log-ratio ,0.05).
doi:10.1371/journal.pone.0019106.g001
KSHV LANA Down-Regulates IL22R1 Expression
PLoS ONE | www.plosone.org 3 April 2011 | Volume 6 | Issue 4 | e19106whether the function of IL-22 is impaired in KSHV-infected cells,
the activation of STAT3 and ERK 1/2 in 293T and 293T-BAC36
cell line in response to IL-22 stimulation was assessed.
Cells were collected at different time points after IL-22 was
added to the culture media to a final concentration of 100 ng/ml.
As shown in Figure 6, STAT3 and ERK 1/2 were activated in
293T cells only 5 min after treatment with IL-22. However, in
293T-BAC36 cells, in which BAC36 virions have established
stable latent infection [41], it took 30 min of IL-22 treatment for a
similar level of STAT3 and ERK 1/2 phosphorylation to occur.
The BCBL-1 cell line treated with IL-6 was used as a control to
monitor the activation of STAT3 and ERK 1/2 [42,43]. These
results suggested that KSHV-infected cells showed impaired
responses to IL-22 stimulation, which may attribute to the
decreased expression level of IL-22R1 in these cells.
Discussion
KSHV is the causal agent of Kaposi’s sarcoma (KS) and all
forms of KS are characterized by the proliferation of spindle-
shaped cells. The vast majority of spindle cells is latently infected
and expresses only a small subgroup of viral proteins, including
LANA [44]. In addition to tethering viral episomal DNA to the
chromosomal DNA, KSHV LANA is well known as a transcrip-
tion factor since it can activate as well as repress transcription.
LANA activation of transcription is directed by multiple promoters
containing binding sites for a range of cellular proteins that mostly
linked to a TATA box [16]. And studies have shown that LANA
can bind to various transcription factors like RING3 [45], ATF/
CREB2 [17], CREB-binding protein (CBP), mSin3A [19] and
glycogen synthase kinase 3 (GSK-3b) [46] to alter their function in
Figure 2. LANA down-regulates IL-22R1 promoter activity in a dose-dependent manner. (A) Schematic of pIL22R1 (22139 to +39) and a
series of deletion mutants (pIL22R1-D1, D2, D3, and D4). (B) LANA down-regulates IL-22R1 promoter (22139 to +39) activity. pIL22R1 (22139 to +39)
was co-transfected with increasing amounts (0, 0.1, 0.2 or 0.4 mg) of LANA into 293T cells. At 48 h post-transfection, cells were lysed and assayed for
luciferase activity. The expression levels of LANA were detected in cell lysates by western blotting using anti-LANA-C antibody (top panel). The
regulation of the IL-22R1 promoter (22139 to +39) by LANA was also analyzed in HUVEC cells (lower panel).
doi:10.1371/journal.pone.0019106.g002
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not a general processivity factor, as only those genes containing
SRE elements can be activated by LANA [47]. Only a few LANA-
responsive promoters have been identified and most of them are
related to KSHV oncogenesis.
Using luciferase reporter assays, LANA was found to down-
regulate the promoter activity of IL-22R1. When LANA was over-
expressed in both 293T cells and HUVECs, IL-22R1 promoter
activity was altered. Many evidences indicate that LANA is able to
modulate transcription through two distinct mechanisms, interac-
tion with upstream transcriptional regulators or direct binding of
DNA. LANA has been shown to be able to down-regulate the
expression of the virally-encoded K1 gene by directly binding to its
promoter [22]. However, there was no data to demonstrate
Figure 3. The LBS-like sequence is required for LANA to down-regulate IL-22R1 expression. (A) Schematic of pIL22R1 (22139 to +39),
pIL22R1DLBS-like and pIL22R1mLBS-like DNA sequences. (B) Increasing amounts of pcDNA-LANA expressing full-length LANA were co-transfected
with either pIL22R1 (22139 to +39) or its mutants (pIL22R1DLBS-like and pIL22R1mLBS-like) into 293T cells. At 48 h post-transfection, cells were
harvested and assayed for luciferase activity. (C) Increasing amounts of pcDNA-LANA-C-expressing carboxyl-terminal domain (amino acids 951–1162)
of LANA were co-transfected with either pIL22R1 (22139 to +39) or its mutants (pIL22R1DLBS-like and pIL22R1mLBS-like) into 293T cells. At 48 h
post-transfection, cells were harvested and assayed for luciferase activity. (D) Increasing amounts of pcDNA-LANA expressing full-length LANA were
co-transfected with either pIL22R1 (22139 to +39) or its mutants (pIL22R1DLBS-like and pIL-22R1mLBS-like) into HUVEC cells. At 48 h post-
transfection, cells were harvested and assayed for luciferase activity.
doi:10.1371/journal.pone.0019106.g003
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binding to the cellular chromosome DNA. The DNA sequence
required for LANA binding has been identified as the LBS. By
DNA sequence analysis, an LBS-like sequence which differs only
in one nucleotide with LBS reported by Garber et al. [38], was
identified in the 592 64 to 248 region upstream of the IL-22R1
gene. Our data further demonstrate that LANA can bind to this
LBS-like sequence both in vitro and in vivo. Meanwhile, when the
LBS-like region was mutated, the ability of LANA to down-
regulate IL-22R1 was dramatically reduced. We have shown that
the C-terminus of LANA (a.a. 951–1162) is responsible for LBS
binding, and consistent with these observations, we observed that
transiently transfected LANA-C alone can also reduce IL-22R1
promoter activity. The LBS-like sequence in the IL-22R1
promoter is located close to the transcription start site (264 to
248), and the binding of a large protein like LANA may compete
with other transcription factors to cause transcriptional repression.
This is the first report indicating that LANA can bind directly to
the host genomic DNA to regulate cellular gene expression. A
previous report has also shown that LANA can silence TbRI I
gene expression by associating with the promoter of TbR II and
leading to its methylation and to the deacetylation of the proximal
histone. Indeed, KSHV LANA can modulate host gene expression
in a multiple ways. The IL-22R1 promoter lacks a TATA box
near its transcription initiation site but contains a Sp1-like element.
Thus, Sp1 probably plays a role in the regulation of IL-22R1
expression. Previous reports have indicated that LANA can up-
regulate survivin expression by forming a complex with Sp1 or
Sp1-like proteins [48]. When the LBS-like region was deleted from
the IL-22R1 promoter, we did observe the full length of LANA
still can down-regulate IL-22R1 expression at a lower level, but
LANA-C can not. So we speculate that Sp1 may also be involved
in the regulation of IL-22R1 expression by LANA.
IL-22R1 belongs to the Class II cytokine receptors family
(CRF2). The expression levels of IL-22R1 and IL-20R2, which
can form a receptor complex to be recoginzed by IL-20 and IL-
24, are found much lower in KS tissue than in normal tissue,
suggesting that the function of the cytokines might be impaired in
the KS lesion. IL- 20 is an anti-angiogenic cytokine [33], and IL-
24 has also been confirmed as a potent inhibitor of angiogenesis.
This effect is mediated by secreted IL-24 affecting endothelial cell
growth through interactions with the IL-20/IL-22 receptor
complexes [49]. IL-24 is also well known as potential anti-tumor
drug [50]. IL-22 is another cytokine using IL-22R1 as its
receptor. IL-22 is a member of the IL-10 family of cytokines
produced by activated T cells and is involved in several tissue
inflammation responses. The functional IL-22 receptor complex
consists of two chains, IL-22R1 and IL-10R2. Although the IL-
10R2 level did not show the same differences in our study
comparing KS tumor tissue and normal tissue as IL-22R1, we did
observe that KSHV-infected cells had impaired response to IL-22
stimulation. This result suggests that the reduced IL-22R1 levels
may affect the function of associated cytokines. At least in early
stage, KS lesions are thought to be angiohyperplastic-inflamma-
tory lesions mediated by inflammatory cytokines and angiogenic
factors[4]. We also hypothesize that low expression level of IL-
22R1 exacerbates KS pathogenesis.
This report reveals that LANA down-regulates IL-22R1
expression through direct binding to a cis-acting element that
located within the IL-22R1 promoter region. This is the first
report to show that KSHV LANA can regulate host gene
expression by directly binding to the cis-element within the
Figure 4. LANA binds to the IL-22R1 promoter in vitro. (A) The aligned sequences of DNA fragments from TR DNA, wild type and mutant IL-
22R1 promoters which contain LBS, the wild type LBS-like sequence and scrambled-mutant DNA sequence (underlined) [38]. The nucleotide
sequences represent the probe sequences used in the EMSA and were labeled with biotin. (B) LANA can bind to the LBS-like DNA sequence in IL-
22R1 promoter. Probes as indicated were incubated for 20 min with or without purified LANA-C (a.a. 951–1162). NC, a DNA fragment derived from
the sequence in M13 DNA, used as a negative control for LANA binding. (C) The binding of LANA to the wild type LBS-like sequence is specific. A 10-
fold excess of cold competitor or mutant competitor DNA was added to compete the reaction between WT LBS-like and LANA. The upper and lower
arrows indicate the LANA-specific binding band and free probe.
doi:10.1371/journal.pone.0019106.g004
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interaction and viral pathogenesis.
Materials and Methods
Cell culture, antibodies and reagents
Human embryonic kidney cells 293T and 293T-BAC36 (293T
cells harboring KSHV BAC36) were cultured in Dulbecco’s
modified Eagle’s media (GIBCO/BRL) supplemented with 10%
fetal calf serum at 37uC with 5% CO2, and 200 mg/ml of
hygromycin B was added to the 293T-BAC36 culture media.
HUVECs, human umbilical vein endothelial cells, were grown in
M199/EBSS culture media (Thermo) supplemented with 10%
fetal calf serum at 37uC with 5% CO2. Cells were stimulated with
human recombinant IL-22 (Cell Signaling Technologies) for the
indicated times. Rabbit anti-LANA antibody recognizing the C-
terminus of LANA (amino acid 951–1162) was prepared in our
laboratory. Anti-total STAT3, anti-phosphorylated STAT3
(Ser705), anti-ERK and anti-phosphorylated ERK antibodies
were purchased from Cell Signaling Technologies. Anti-IL-22R1
antibody was purchased from Santa Cruz. Anti-Flag antibody
(M2) and anti-actin antibody (AC-15) were purchased from Sigma.
Plasmids
Eukaryotic expression plasmids pcDNA3.1-LANA and
pcDNA3.1-LANA-C (a.a. 951–1162) were generated to express
Figure 5. LANA interacts with the IL-22R1 promoter in vivo. (A) Schematic diagram showing the locations of the two pairs of primers used in
the ChIP assay. (B) Formaldehyde cross-linked chromatin was prepared from 293T cells that were transfected with pFLAG, pFLAG-LANA, pFLAG-
LANA1–939 or pFLAG-LANA933–1162, and immunoprecipitated with anti-FLAG antibody. PCR was performed with primer pair 1 to amplify a 197 bp DNA
fragment containing LBS or with primer pair 2 to amplify a 283 bp DNA fragment, approximately 2 kb upstream of LBS-like sequence in IL-22R1
promoter. A sample representative of 5% the total input chromatin was included in the PCR analysis. (C) The expression levels of LANA and its
truncated mutants were detected in cell lysates by western blotting using anti-FLAG antibody and anti-actin served as a loading control.
doi:10.1371/journal.pone.0019106.g005
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fragment containing the LANA open reading frame was amplified
with the primers 59-CCCCCCAAGCTTATGGCGCCCCCGG-
GAATG-39 (forward), 59-CCGCCGGAATTCTTATGTCAT-
TTCCTGTGGAGAGTC-39 (reverse) for full-length LANA and
59- GCGCCCAAGCTTATGGATTACCCTGTTGTTAGCA-
CA-39 (forward), 59-GGCCGCGAATTCTTATGTCATTT-
CCTGTGGAGA-39 (reverse) for LANA-C by PCR from
BCBL-1 Hirt-DNA and were then cloned into the HindIII and
EcoRI sites of the pcDNA3.1 plasmid. pSG5-FLAG-LANA was a
gift of Kenneth M. Kaye (Harvard University) [10]. FLAG tagged
truncated LANA mutant cDNA were amplified using PCR and
cloned into pCMV-FLAG to produce FLAG-LANA1–939 (1–939
a.a.), FLAG-LANA933–1162 (939–1162 a.a.). Primer 59-
CCAAGCTTATGGCGCCCCCGGGAATGCGCCTG-39 (for-
ward), 59-CGGAATTC TTA TGTCATTTCCTGTGGA-
GAGT-39 (reverse) for amplifying LANA1–939 and 59-
CCAAGCTTATGGCGCCCCCGGGAATGCGCCTG-39 (for-
ward), 59-CGGAATTCTTACAAGATTATGGGCTCTTC-
CACCGT-39 (reverse) for amplifying LANA933–1162. The reporter
plasmid pIL22R1 was constructed by cloning the 59 untranslated
DNA sequence of IL-22R1 22139 to +39 (+1 being the initiation
site) into the pGL3-basic vector (Promega) at the 59 MluI site and
the 39 XhoI site. This fragment was PCR amplified using BJAB
genomic DNA as the template. pIL22R1DLBS-like and pIL22R1-
mLBS-like were constructed by inserting an EcoRI/XhoI DLBS
(lacking the 14 bp LBS-like sequence ) or mutant LBS fragment
containing a random rearrangement of the 14 bp LBS-like
sequence (ACCGGCTCCGCGCG) to replace the EcoRI/XhoI
fragment of pIL22R1. A series of truncated mutants of pIL22R1
were also constructed by PCR, and the fragments were inserted
into pGL3-basic. Primers used in construction of luciferase
plasmids are shown in Table 1. These constructs were all
confirmed by DNA sequencing (Invitrogen).
Transient transfection and western blot analysis
All plasmids for transfection were purified by QIAGEN
miniprep kit. Transfection of HUVEC cells and 293T cells was
performed using the Lipofectamine 2000 reagent (Invitrogen)
according to the manufacturer’s instructions.
Protein expression levels were measured by western blotting. At
the time of harvest, cells were washed by ice-cold PBS (phosphate-
buffered saline) and lysed in RIPA lysis buffer. Lysates were
prepared and subjected to sodium dodecyl sulfate-polyacrylamide
gel electrophoresis (SDS-PAGE), followed by electrotransfering
onto immobilon-p polyvinylidene difluoride membranes (Milli-
pore, Bedford, MA). The membranes were incubated in blocking
buffer (50 mM Tris-HCl [pH 7.4], 0.2 M NaCl containing 5%
non-fat milk and 0.1% Tween) for 1 h followed by incubation with
primary antibodies overnight at 4uC. The membranes were then
washed with TBS-T and incubated with HRP-conjugated goat
anti-mouse or anti-rabbit antibody (Thermo) for 1 h at room
temperature. Signals were detected with enhanced-chemilumines-
cence substrate (ECL; Thermo) and an AlphaEaseH FC Imaging
System (Alpha Innotech Corporation).
EMSA
Electrophoretic mobility shift assay was carried out as described
by Shin & Park [51] with modifications. The double-stranded
oligonucleotides were prepared by annealing sense and anti-sense
oligonucleotides which were 59 end-labeled with biotin. Each
binding reaction mixture containing 20 mM Tris/HCl (pH 7.4),
100 mM NaCl, 4 mM MgCl2, 0.25 mM EDTA, 1 mM dithio-
threitol, 0.5 mg poly (dI-dC), 10% (v/v) glycerol, 100 ng labeled
oligonucleotide and 0–400 ng purified LANA-C (a.a. 951–1162)
protein. After incubation at room temperature for 20 min,
reaction mixtures were separated on 6.5% native polyacrylamide
gels. Electrophoresis was performed in 0.56 TBA (Tris-borate-
EDTA) at 100 V on ice. The DNA-protein complexes were
transferred onto Hybond-N
+ membranes (Amersham) and were
immunoblotted with HRP-conjugated streptavidin. Signals were
examined with enhanced-chemiluminescence substrate (ECL;
Thermo) and an AlphaEaseH FC Imaging System (Alpha Innotech
Corporation).
Chromatin immunoprecipitation (ChIP) assay
A total of 5610
6 293T cells were transfected with 12 mgo f
pCMV-FLAG, pSG-FLAG-LANA, pFLAG-LANA1-939,o r
pFLAG-LANA933–1162. At 48 h post-transfection (p.t.), the cells
were collected and treated with formaldehyde for 10 min followed
by the addition of glycine to a final concentration of 0.125 M.
Cells were then washed twice with cold PBS and were resuspended
in lysis buffer (1% SDS, 10 mM EDTA, 50 mM Tris-HCI,
Figure 6. KSHV-infected cells show impaired response to IL-22
stimulation. 293T and 293T-BAC36 cells are stimulated with 100 ng/
ml of rIL-22 for 0, 5, 15, or 30 min. The cells were lysed and subjected to
immunoblot analysis to detect the phosphorylation of STAT3 and ERK.
doi:10.1371/journal.pone.0019106.g006
Table 1. Sequences of the primers used for the generation of
luciferase reporter plasmids.
Primer Name Sequence (59-39)
pIL22R1(+)C G ACGCGTCAAGCAATTCTCCTGCTTCAGC
pIL22R1(2) CCGCTCGAGCGGGGCTGGCACAGAGCCCTCCC
pIL22R1-D1(+)C G ACGCGTGCTTCCCCACACTGCCTTGTCATCA
pIL22R1-D2(+)C G ACGCGTAAATGACTGGCATGGGCCCTACCTT
pIL22R1-D3(+)C G ACGCGTATGAAGTTCAGCCCCATCTCTAGCA
pIL22R1-D4(+)C G ACGCGTACCCCAAGCGTGGGGACCTGCCTTG
mLBS-like(+)a GCGGAATTCCAGAGCACACAGGGCCAGGAC
mLBS-like(2) CACGCGCGGAGCCGGTGGGGAGAAGGGGGTGGGTGGGAC
mLBS-like(+)b CCACCGGCTCCGCGCGTGGAGCCAGCTGCCAGGGCGCCA
DLBS-like(2) GCTGGCTCCAGGGGAGAAGGGGGTGGGT
DLBS-like(+) CCTTCTCCCCTGGAGCCAGCTGCCAGGGCG
Restriction enzyme sites are underlined.
doi:10.1371/journal.pone.0019106.t001
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the DNA to an average fragment size of 200–1000 bp, the DNA
fragments cross-linked to proteins were enriched by immunopre-
cipitation with an anti-FLAG antibody overnight at 4uC. After
reversal of the cross-linking and DNA purification, the extent of
enrichment was monitored by PCR amplification. PCR was run at
95uC for 30 s, 55uC for 35 s, and 72uC for 1 min. The primers for
the LBS region were 59-CTCCCTTAGATCCCGCCCA-
GAACCT-39 (forward) and 59- GAGCCCTCCCTTGGCCTC-
TACTC-39 (reverse). The primers for the non-LBS fragments used
as negative control were 59-GCAATTCTCCTGCTTCAGC-
CTCCCG-39 (forward) and 59- GAACACCCAGACTT-
CATTTCTAACA-39 (reverse).
Luciferase assay
Luciferase reporter plasmids, pRL-TK plasmid, pcDNA3.1-
LANA, pcDNA3.1-LANA-C, or pcDNA3.1 empty vector were
mixed and transfected into cells. After 48 h, the cells were
collected. A luciferase assay was performed with the Dual
Luciferase Reporter Assay System (Promega) according to the
manufacturer’s protocols. The relative values of firefly luciferase
activity were determined by normalizing to Renilla luciferase
activity for transfection efficiency.
cDNA microarray and data analysis
Total RNA of frozen sections of AIDS-KS lesions and
surrounding normal tissue from the same patients were extracted
using TRIzol reagent (Invitrogen), followed by purification on an
RNeasy column (Qiagen) and quantified by UV absorption
(Nanodrop). RNA quality was assessed with a 2100 bioanalyzer
and the RNA 6000 LabChipR (Agilent Technologies). The SBC
homemade human cDNA microarray (Shanghai, China) contain-
ing 15552 spots (including 768 controls and 14784 probes) was
used to evaluate the expression level of 10379 known genes and
3022 ESTs. The microarray was made as previously described
(Huang et al., 2006). An Agilent Low RNA Input Fluorescent
Linear Amplification Kit (Agilent Technologies) was used for RNA
linear amplification following the manufacturer’s protocol. RNA
samples from normal tissue were pooled and used as a reference
labeled with Cy3 (GE Healthcare). RNA from KS tissue was
isolated in triplicate and labeled with Cy5 individually. Cy3- and
Cy5-labeled cRNA pools were mixed to hybridize to the
microarrays. Hybridization and washes were performed using a
standard protocol followed by scanning on an Axon 4000B
Scanner (Axon Instruments). Microarray raw data intensity
profiles were analyzed using GeneSpring 7 (Agilent technologies)
to perform locally weighted scatter plot smoothing (LOWESS)
normalization and statistical analysis. The normalized data were
then subjected to zeroing and normal tissue samples served as the
zeroes. Changes in gene expression were considered significant if
the detection P value was less than 0.05 (log-ratio p value,0.05)
and the magnitude of the change was at least 2-fold.
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